Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with
anticonvulsant properties, was approved by the US Food and Drug Administration (FDA) in …

Background: One in five individuals live with chronic pain globally, which often co-occurs
with sleep problems, anxiety, depression, and substance use disorders. Although these …

Cannabis sativa and related products are widely used, but their potential to cause significant
clinical interactions remains unclear, particularly for cannabinoid-enriched or otherwise …

As a therapeutic agent, most people are familiar with the palliative effects of the primary
psychoactive constituent of Cannabis sativa (CS), Δ 9-tetrahydrocannabinol (THC), a …

Although prescribing information (PI) is often the initial source of information when
identifying potential drug-drug interactions, it may only provide a limited number of …

Abstract In the United States, the evolving landscape of state-legal marijuana use for
recreational and/or medical purposes has given rise to flourishing markets for marijuana and …

Abstract Delta‐9‐tetrahydrocannabinol (THC), the main psychoactive cannabinoid in
cannabis, may inhibit the cytochrome P450 enzyme CYP2C9. Consequently, cannabis use …

Multidrug resistance caused by the overexpression of ABC drug transporters is a major
obstacle in clinical cancer chemotherapy. For several years, it appeared that direct inhibition …

P-glycoprotein (Pgp or ABCB1) is an ABC transporter protein involved in intestinal
absorption, drug metabolism, and brain penetration, and its inhibition can seriously alter a …

Objective Cannabidiol is efficacious as an adjunctive treatment in children with epilepsy
associated with Dravet and Lennox-Gastaut syndromes. As its role is currently adjunctive …